Pierre Fabre & Puma Biotechnology Enter into Exclusive License Agreement

Apr 4, 2019 | HER2-Positive Breast Cancer, Oncology

Breast Cancer

Pierre Fabre and Puma Biotechnology, Inc have entered into an exclusive license agreement. Pierre Fabre will develop and commercialize NERLYNX® (neratinib) within Europe and part of Africa. The European Commission recently granted marketing authorization for NERLYNX® for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer who are less than one year from the completion of prior adjuvant trastuzumab-based therapy.


Pin It on Pinterest